# Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia

> **NCT01327859** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 357 (actual)

## Conditions studied

- Parkinson's Disease
- Dementia

## Interventions

- **DRUG:** Prior Donepezil 5mg
- **DRUG:** Prior Donzepezil 10mg
- **DRUG:** Prior Placebo

## Key facts

- **NCT ID:** NCT01327859
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327859, "Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01327859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*